Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名:Mereletinib

Osimertinib (AZD9291)化学構造

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ 価格(税別)  
JPY 18100
JPY 24400
JPY 118200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(221)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
特性 Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
ターゲット
L858R/T790M EGFR [1]
(LoVo cells)
Exon 19 deletion EGFR [1]
(LoVo cells)
WT EGFR [1]
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-9/BRc1 M1;ZSWZ2dmO2aX;uJGF{e2G7 M2\CUlUxKG6P NYjaOmN1OjRiaB?= NUPsPWdyTE2VTx?= NI\oRZFqdmS3Y3XzJIV5eHKnc4Ppc44hd2ZidHjlJJBzd2Gyb4D0c5Rq[yCEQ1ytNkBn[W2rbImgcYVu[mW{IFLJUS=> NXLqTZBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1 M2T6fmZ2dmO2aX;uJGF{e2G7 NFyxXY82OCCwTR?= M2HPN|I1KGh? MWjEUXNQ NV7UfZd6cW6mdXPld{BmgHC{ZYPzbY9vKG:oIITo[UBxem:jcH;weI91cWNiQlPMMVIh\mGvaXz5JI1mdWKncjDCTW0> NHLHbnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O|MzPSd-MkW0O|c{OjV:L3G+
VP-2 NXnmXmp3TnWwY4Tpc44hSXO|YYm= NWmz[G42PTBibl2= MV:yOEBp NWjsS4xlTE2VTx?= M{nlU4lv\HWlZYOg[ZhxemW|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN NVjvZ3RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPOVAhdk1? NY\5[XVNOTBiZB?= M4rwRWROW09? M1vQOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gcI9v\y22ZYLtJEgyOC2mYYmpJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7cx?= NXu3bldFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu1NEBvVQ>? NXjYOllGOTBiZB?= NXS4eW1XTE2VTx?= MX7pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq1NEBvVQ>? NFfnSVQyOCCm NUe0SmpxTE2VTx?= MorzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm| NUT6fWVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC9 GR4 Ml;3SpVv[3Srb36gRZN{[Xl? NUjwV|ZiOC1zMDFOwG0> MUW3NkBp MVnpcohq[mm2c9MgSWdHWiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nxsA> M3j5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 NUX2RWxnTnWwY4Tpc44hSXO|YYm= NX3CXJNROC1zMDFOwG0> MUW3NkBp NY\Qb3dlcW6qaXLpeJMhX1RiRVfGVkBifCCub4egZ49v[2WwdILheIlwdnN? NV;icHJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN|PD;hQi=>
PC9 GR4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjC[ZFMOC1zMDFOwG0> MkTxO|IhcA>? MlfIbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MofxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N|MoRjJ3OUS4OlM{RC:jPh?=
BAF3 MXPGeY5kfGmxbjDhd5NigQ>? M{jYOVczKGh? NWTY[YpET0l3MDC9JFAvODByMzFOwG0> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 M1LQWGZ2dmO2aX;uJIF{e2G7 M1fVXlczKGh? MWfHTVUxKD1iMD6wNFA{KM7:TR?= Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3 NUTWNlc1TnWwY4Tpc44h[XO|YYm= NVnNO3dTPzJiaB?= MXfHTVUxKD1iMD6wNFEh|ryP NWG5dGR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827 NXv3W4JxTnWwY4Tpc44h[XO|YYm= NG\jUHk4OiCq MoPtS2k2OCB;IECuNFAyKM7:TR?= NXq0T21xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9 NIK3NVhHfW6ldHnvckBie3OjeR?= NYDVPVF6PzJiaB?= MU\HTVUxKD1iMD6wNFIh|ryP NWLSXWJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 NGHJ[HFHfW6ldHnvckBie3OjeR?= MnTKOEBp MWTFR|UxKD1iMD6wNFIh|ryP NHLtXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 M{HOcGZ2dmO2aX;uJIF{e2G7 NULQUosyOyCq Mk\rTWM2OCB;IECuNFAzPSEQvF2= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR|M{iyPUc,Ojd2M{O4Nlk9N2F-
H1975 MoXGSpVv[3Srb36gZZN{[Xl? M4\mSVMhcA>? NFXyTmtKSzVyIE2gNE4xODJ3IN88US=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR|M{iyPUc,Ojd2M{O4Nlk9N2F-
H3255 M17VXGZ2dmO2aX;uJIF{e2G7 NFzUSGc{KGh? NHTrc2pKSzVyIE2gNE4xODRzIN88US=> M1ywTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN|gzQTxxYU6=
NCI-H1975 NVi0U2kxTnWwY4Tpc44h[XO|YYm= NH7ZcVU4OiCq NIH4S|JIUTVyIE2gNE4xODVizszN NYK0XGR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9 NEDqXoZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M4[0VVczKGh? MmjaTWM2OCB;IECuNFA3PSEQvF2= M2PXO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G2OlQyLz5{OEexOlY1OTxxYU6=
NCI-H1975 NHnHU3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NEWze|Q4OiCq NV3pNnZKUUN3MDC9JFAvODFyNTFOwG0> NG\ZOlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
Sf21 MYrGeY5kfGmxbjDhd5NigQ>? M4nDUGlEPTBiPTCwMlAyOiEQvF2= MlvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
PC9-DRH NGrTV|VHfW6ldHnvckBie3OjeR?= MVuyJIg> M3PkTWlEPTBiPTCwMlAyOyEQvF2= NFjxe5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3 NFvITFJHfW6ldHnvckBie3OjeR?= NUjlSmg1PzJiaB?= NHTF[FJIUTVyIE2gNE4xOTNizszN M1nHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827 M1XKemZ2dmO2aX;uJIF{e2G7 NXXhcG1lQTZiaB?= Mk\jSWM2OCB;IECuNFE1KM7:TR?= M1HsT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
HCC827 MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NUX3SZh7QTZiaB?= M3HEXGVEPTBiPTCwMlAyPCEQvF2= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
NCI-H1975 NEfuVphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NIj0RoY6PiCq M1LyO2VEPTBiPTCwMlAyPCEQvF2= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
NCI-H1975 MnfNSpVv[3Srb36gZZN{[Xl? NEfSPXQzKGh? NIjLN|lKSzVyIE2gNE4xOTVizszN Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H1975 MkfoSpVv[3Srb36gZZN{[Xl? Mm[yNkBp NILrbYNKSzVyIE2gNE4xOTVizszN NFq2cIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9 NUD2Nnc4TnWwY4Tpc44h[XO|YYm= NH\FZ3gzKGh? NYHoN|BGUUN3MDC9JFAvODF5IN88US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
NCI-H1975 NHTWbopCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NHrtcIg4OiCq M1zUeWlEPTBiPTCwMlAyQSEQvF2= M1;nd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O|c{Lz5{OUS2Olc4OzxxYU6=
NCI-H1975 MnTWSpVv[3Srb36gZZN{[Xl? NEjndZk6PiCq MoS4SWM2OCB;IECuNFE6KM7:TR?= MknYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
NCI-H1975 NVeyb3VjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NVrwd2FIQTZiaB?= M3K2c2VEPTBiPTCwMlAyQSEQvF2= NF\PWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN|k6OSd-Mki2NFM6QTF:L3G+
NCI-H1975 NFvEPINCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NUfHc|lIPzJiaB?= NULT[no1UUN3MDC9JFAvODF7IN88US=> MmqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
HCC827 M{jTNmZ2dmO2aX;uJIF{e2G7 NWLTeoF4OiCq NIfCUmxKSzVyIE2gNE4xOjNizszN NXWxdFJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
NCI-H1975 NXr5OllMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MmjzO|IhcA>? NWi0PZN[UUN3MDC9JFAvODJ|IN88US=> MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
PC9 MWPDfZRwfG:6aXPpeJkh[XO|YYm= NH;WfmQ4OiCq M3zHbmdKPTBiPTCwMlAzOyEQvF2= Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975 MW\DfZRwfG:6aXPpeJkh[XO|YYm= NEHTfYk4OiCq MkHjS2k2OCB;IECuNFI1KM7:TR?= M3PGOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
HCC827 NVfGSHBGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MYK3NkBp MlLKTWM2OCB;IECuNFI2PCEQvF2= NF:1RYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O|YzPzJ:L3G+
HCC827 NH:2RWFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NV7zS3NpPzJiaB?= M1v5R2lEPTBiPTCwMlAzPyEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
HCC827 M1PKRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NIXJN5E4OiCq M4\TXWlEPTBiPTCwMlAzPyEQvF2= NIf6WHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975 MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NHfrNYQ4OiCq NVu1[oY2UUN3MDC9JFAvODNizszN M3;TXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN|U4QTxxYU6=
H3255 NIrvcIVHfW6ldHnvckBie3OjeR?= NVG0T5B6PzJiaB?= MX7HTVUxKD1iMD6wN|Mh|ryP NW\vOHN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255 NYXEPVczTnWwY4Tpc44h[XO|YYm= MWCyJIg> NXPacHJzUUN3MDC9JFAvODN4IN88US=> M3fWXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975 NVS5boxoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NXPYWIgxPzJiaB?= M{\rVGlEPTBiPTCwMlA1OSEQvF2= NXriRohbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
NCI-H1975 M2XmdWZ2dmO2aX;uJIF{e2G7 M1jBRlEhcA>? MVPJR|UxKD1iMD6wOFEh|ryP NI\QU2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N|Q6OjZ:L3G+
BAF3 MUDGeY5kfGmxbjDhd5NigQ>? NH3Zb|Q1KGh? NH3XbppGSzVyIE2gNE4xPDNizszN M{m1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 NE\XNIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NXv3TI1PPzJiaB?= NGTJOm1KSzVyIE2gNE4xPDd{IN88US=> NYrrZZlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O|YzPzJpPkK5OVc3Ojd{PD;hQi=>
NCI-H1975 NHnkcoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MVq3NkBp M3HMR2lEPTBiPTCwMlA2OiEQvF2= NHzrZ4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN|E3Ozl:L3G+
PC9 M2DiRWZ2dmO2aX;uJIF{e2G7 MonsNkBp MonHTWM2OCB;IECuNFU3KM7:TR?= NIWyTYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975 NFP3Z|VEgXSxdH;4bYNqfHliYYPzZZk> NEPGdlg4OiCq M4L1W2lEPTBiPTCwMlA3KM7:TR?= M13neVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEi2PVU{Lz5{OUS4Olk2OzxxYU6=
HCC827 Ml;QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXrOcIM{UUN3MDC9JFAvODZzNjFOwG0> M1XXZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
NCI-H1975 M2fPdWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NEjZPFFKSzVyIE2gNE4xPjdizszN M2TIclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT MYHGeY5kfGmxbjDhd5NigQ>? NUX5Z2JZOyCq M1fGR2lEPTBiPTCwMlA4OzdizszN NUP2XlJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0N|M5OjlpPkK3OFM{QDJ7PD;hQi=>
NCI-H1975 M2HSS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NELZRnM4OiCq M17HdGlEPTBiPTCwMlE{KM7:TR?= MlP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
A431 MlrXSpVv[3Srb36gZZN{[Xl? NWW2epg5OSCq NUTESY05UUN3MDC9JFAvOTRzIN88US=> NWPDTIZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549 NH7pVmRHfW6ldHnvckBie3OjeR?= NX2yW3dGUUN3MDC9JFAvOTVizszN M{X0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
Calu3 MYXDfZRwfG:6aXPpeJkh[XO|YYm= NWCxZWNuPzJiaB?= MWHHTVUxKD1iMD6yOlQh|ryP M{eyZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
Sf9 MoDjSpVv[3Srb36gZZN{[Xl? NIXG[mYzOCCvaX7z NUfJToJFUUN3MDC9JFAvOjd6IN88US=> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR6MkG1NUc,Ojh2OEKxOVE9N2F-
BAF3 NGrFc2JHfW6ldHnvckBie3OjeR?= MWC3NkBp NYLz[m55T0l3MDC9JFAvOyEQvF2= NVXSeGhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 NGXsUYRHfW6ldHnvckBie3OjeR?= NGDOUnI4OiCq MlrKS2k2OCB;IECuN|Eh|ryP M2\PXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H460 MkfYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MUe3NkBp MmSwTWM2OCB;IECuOFE2QSEQvF2= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
LoVo M4fIfGZ2dmO2aX;uJIF{e2G7 NHXkbIwzKGh? NWW0NXV{UUN3MDC9JFAvPDhizszN MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo NYP0NGJKTnWwY4Tpc44h[XO|YYm= MXWyJIg> NXq0RmxWUUN3MDC9JFAvPDhizszN NIrx[5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
A549 M4LBU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M{XLflczKGh? NYDFPIt2UUN3MDC9JFAvPDh4IN88US=> MnXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO|IoRjJ7NUe2NlczRC:jPh?=
BAF3 NVK0V4xETnWwY4Tpc44h[XO|YYm= NYP5XIdxPzJiaB?= M1v4eWdKPTBiPTCwMlUh|ryP M33XS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549 NEnvV|dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MX:3NkBp NH;UeJdKSzVyIE2gNE42OyEQvF2= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
A549 MXXDfZRwfG:6aXPpeJkh[XO|YYm= NWe5XllzPzJiaB?= NH3y[YlKSzVyIE2gNE42OyEQvF2= NXjVRW93RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
BAF3 NFG4OmlHfW6ldHnvckBie3OjeR?= NF7tZZU4OiCq MkX0S2k2OCB;IECuOVUh|ryP NYTQO3pHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 MXzGeY5kfGmxbjDhd5NigQ>? NHPF[Fk4OiCq NWjMWow5T0l3MDC9JFAvPTZizszN NYnP[JVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HEK293 M{S0dmZ2dmO2aX;uJIF{e2G7 MWHJR|UxKD1iMD61O{DPxE1? M4Xwe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
BAF3 MljoSpVv[3Srb36gZZN{[Xl? MmTwO|IhcA>? Mkf0S2k2OCB;IECuOVkh|ryP MmrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A431 NITKeZNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NGH2[HJKSzVyIE2gNE43OTV4IN88US=> MkX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HT-29 MlT5R5l1d3SxeHnjbZR6KGG|c3H5 NGrI[mo4OiCq MXrJR|UxKD1iMD62OUDPxE1? NUPLW5FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV|PD;hQi=>
A431 NFfhWYxHfW6ldHnvckBie3OjeR?= MUm5OkBp Mkm3SWM2OCB;IECuOlY4KM7:TR?= M{\v[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431 NYfLToNjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NFfkcYg6PiCq M1XOTmVEPTBiPTCwMlY4KM7:TR?= M3HFW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
A431 NX7zXJpUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M4XvWFczKGh? NVfSWXR4UUN3MDC9JFAvPjh3IN88US=> NFfLTZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N|Q6OjZ:L3G+
A431 NFrBd2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NY[yVJR3QTZiaB?= M3PaVWVEPTBiPTCwMlch|ryP MlniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
A549 NH3VfZREgXSxdH;4bYNqfHliYYPzZZk> Mle0O|IhcA>? NIPoO2pKSzVyIE2gNE45PyEQvF2= NV3DeJpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV|PD;hQi=>
A431 M4ntbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWe3NkBp NEXDVllKSzVyIE2gNE45QTNizszN MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MU[zPUc,OjdzM{G2N|k9N2F-
BA/F3 M17sbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MmizO|IhcA>? MXnJR|UxKD1iMTFOwG0> M2naNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3 NGLRZ4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXSwdW16PzJiaB?= MXnHTVUxKD1iMT6yJO69VQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H2122 NVH6RZQ6TnWwY4Tpc44h[XO|YYm= NUTUNZdGPzJiaB?= NU\vNWZFT0l3MDC9JFEvOiEQvF2= NGPX[|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431 NFvwXpdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NV\UenJLPzJiaB?= NYriW5VkUUN3MDC9JFEvOjRizszN MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431 NUTyXFFoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NIXFS4o4OiCq MUHJR|UxKD1iMT6yOkDPxE1? M13FSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
A431 Mkj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4m4VVczKGh? MXXJR|UxKD1iMT62NFQh|ryP Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{O1O|koRjJ6MEOzOVc6RC:jPh?=
A549 NGjRcIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M3fzTFk3KGh? NWrRVHdLTUN3MDC9JFEvQDNizszN M3vSblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
CHL NHTNe5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnXGO|IhcA>? MmC0S2k2OCB;IEKuPUDPxE1? MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1355 NIDpe49HfW6ldHnvckBie3OjeR?= M{DwS|czKGh? M4HMTGdKPTBiPTCzJO69VQ>? MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703 MULGeY5kfGmxbjDhd5NigQ>? NV;ifIVrPzJiaB?= Mm\OS2k2OCB;IEOuOUDPxE1? NFfVVIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A549 MnXLSpVv[3Srb36gZZN{[Xl? NYPmNVlrPzJiaB?= NEPoVphIUTVyIE2gN{42KM7:TR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
CHO MkLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLBO|IhcA>? NUjVRZlrT0l3MDC9JFQvOiEQvF2= M{TufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3 M3PvfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MUO3NkBp M4TVXmlEPTBiPTC0MlYyKM7:TR?= NX;Dc3RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BAF3 MlziRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYDG[HdIPzJiaB?= NIfubHpKSzVyIE2gOU4yPSEQvF2= NFnmb|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
BEAS2B M2nLOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVnKT3E6PzJiaB?= NUS4VmF{UUN3MDC9JFE1NjlizszN MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975 NYDwSlRMTnWwY4Tpc44h[XO|YYm= NHLGSGIzKGh? NIG1emtKSzVyIE2gNVUh|ryP NXfpZ5FWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
PC9 MWLGeY5kfGmxbjDhd5NigQ>? MWOyJIg> MkPyTWM2OCB;IEG3JO69VQ>? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
LoVo M3S2XGZ2dmO2aX;uJIF{e2G7 M3LvfFIhcA>? MUTJR|UxKD1iNEiwJO69VQ>? NIHNS|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
NCI-H1975 MnzGRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7 NV2zNY1mSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB{LkWgcYcwc2dxZHH5MEBxdyCzZDDmc5IhPyCmYYnzJJJmdGG2aY\lJJRwKGOxboTyc4w> NH\t[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
rat hepatocytes NWD4OlJJTnWwY4Tpc44h[XO|YYm= NF\KbmVKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=> NVTicHhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
human hepatocytes MXPGeY5kfGmxbjDhd5NigQ>? NVjyOoE1UW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDt[YF{fXKnZDDw[ZIhOTBpNjDj[Yxtew>? MlfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975 NU\KcGgySW62aYT1cY9zKGGldHn2bZR6KGG|c3H5 MX\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x? M{fVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 Mn6xSpVv[3Srb36gZZN{[Xl? MmrNV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B1dyCLQ{WwJIZweiC5aXzkJJR6eGViRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGE1OzFiY3XscJM> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975 MY\BcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? MVjBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDFS2ZTKFR5OUDNM2w5PTiUIHTveYJt\SCvdYThcpQh\XiycnXzd4lv\yCqdX3hckBPS0lvSEG5O|Uh[2WubIOgfIVvd2e{YX\0[YQhcW5iQlHMRk9kKGG2aIntbYMhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZzygdI8h[mmmIH\vdkAzOSCmYYnz M2rpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827 NIPMRnVCeG:ydH;zbZMh[XO|YYm= NG\B[I5KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIViemy7IHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCxMlM1LSl? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O|M9N2F-
HCC827 M{\veWFxd3C2b4Ppd{Bie3OjeR?= MoDpTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKQ1O4Nlch[2WubIOgbIFz[m:{aX7nJGVITlJiRUe0Ok1CPzVyIHTlcIV1cW:wIH31eIFvfCCjc4Pld5Nm\CCjczDsZZRmKGGyb4D0c5Rq[yClZXzsd{BifCB|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSB{Nz6xOEUq NHzDb2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549 Mk\oSpVv[3Srb36gZZN{[Xl? NULYUHh5W2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ> Mn\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827 NHjCbYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1XzSVczKGh? MnXDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ1O4Nlch[2WubIOgZZQhOSC3TTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y= M{LYbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3 NFq5cnFHfW6ldHnvckBie3OjeR?= NUK4O25sOiCq MV7Jcohq[mm2aX;uJI9nKEWJRmKgWFc6OE1xTEi1PHIwSzd7N2OgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXHSk1qdmS3Y3XkJJJm[2WydH;yJJBpd3OyaH;yfYxifGmxbjDheEAyKHSxIEOgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBGT0Zic4TpcZVt[XSrb36g[o9zKDF3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NXvTbm9FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTZpPkOwOFI6QTV4PD;hQi=>
BAF3 M3LLeWZ2dmO2aX;uJIF{e2G7 MkTjNkBp MWPJcohq[mm2aX;uJI9nKEWJRmKgNVlFN1R5OUDNM2M4QTeVIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHR1[tbY5lfWOnZDDy[YNmeHSxcjDwbI9{eGixconsZZRqd25iYYSgNUB1dyB|IIXNJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyPSCvaX7zJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NFLmXVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
NCI-H1975 NUnJN4tLSW62aYT1cY9zKGGldHn2bZR6KGG|c3H5 MmXrRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJHNVV0ONLV\vfI4ydnVxTnr1JI52\GVibX;1d4Uh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDndo94fGhiYYSgNlAhdWdxa3ev[IF6NCCybzDx[EBnd3JiMUSg[IF6eyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= MoPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|OUWyNVkoRjJ6M{m1NlE6RC:jPh?=
Caco2 M1\IW2Z2dmO2aX;uJIF{e2G7 NF;yWpIzKGh? NG\ZcVJG\m[udYigdoF1cW9ib3[gZZBx[XKnboSgdIVzdWWjYnnsbZR6KG[{b32gZoF{d2yjdHXyZYwhe2mmZTD0c{BieGmlYXygd4ll\SCxdnXyJIFxcWOjbDDzbYRmKHSxIHLhd49t[XSncnHsJJNq\GVib4\ldkBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? MmXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
A431 MnvYSpVv[3Srb36gZZN{[Xl? NEDSbZhU\WynY4Tpeol1gSC{YYTpc{Bw\iCHQ{WwJIZweiCqdX3hckBCPDNzIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnIhfG9iRVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[ULVy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnR? MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
Caco2 Ml\ySpVv[3Srb36gZZN{[Xl? NIDzbpYzKGh? MkHGRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? M1LhZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
Caco2 MnLHSpVv[3Srb36gZZN{[Xl? MmfMNkBp MnvkRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{Bj[XOxbHH0[ZJidCC2bzDhdIlk[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? MnvCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
NCI-H1975 M2XBN2Z2dmO2aX;uJIF{e2G7 M{\OVlQhcA>? MX3Jcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQXv0JJBpd3OyaH;yfYxifGmxbjDheEBVcHJ|MEivV4VzPDd|IIPpeIUh[XRiMTD1UUBu\WG|dYLl[EBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NH7J[lE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 NWn5b3dVTnWwY4Tpc44h[XO|YYm= NHzJRXI1KGh? NUPyRWR6UW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIlvKGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSWu2IIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhxU3XyOFc{KHOrdHWgZZQhOSC3TTDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M2TsbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 MkTERZBweHSxc3nzJIF{e2G7 MYe0PEBp M2H0TWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?= M37LSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827 NFfle3BCeG:ydH;zbZMh[XO|YYm= NWmxT45mPDhiaB?= M1;IfGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG|c3Xzd4VlKGG|IHPhd5Bie2VvMzDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> MmDhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9 MlHjRZBweHSxc3nzJIF{e2G7 NIG3RVM1QCCq Mo\HTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMh[2G|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIludXWwb3Lsc5R1cW6p Mk\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H3255 M37qRmFxd3C2b4Ppd{Bie3OjeR?= MkeyOFghcA>? NFm4PXJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 NH:3[29CeG:ydH;zbZMh[XO|YYm= MVG0PEBp M4XiTmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o NXTQRXdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
PC9 MX7BdI9xfG:|aYOgZZN{[Xl? MYW0PEBp M1i2SWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc> M2nJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827 NVnyZ2xlSXCxcITvd4l{KGG|c3H5 NWP5PVBEPDhiaB?= M2rENmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG|c3Xzd4VlKGG|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd? M{jlV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255 MXnBdI9xfG:|aYOgZZN{[Xl? Mln6OFghcA>? MYPJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh|MkW1JINmdGy|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n M2HybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 MYTGeY5kfGmxbjDhd5NigQ>? NU[wZVZMW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDoZZJjd3Krbnege4lt\C22eYDlJGVITlJ? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
human hepatocytes Mkj4SpVv[3Srb36gZZN{[Xl? MmmzTY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgcYltdGmxbjDj[Yxtew>? M3;wTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
rat hepatocytes Mn;LSpVv[3Srb36gZZN{[Xl? M2XzSGlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{ NHW2Sm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
A549, NCI-H1975 NH23N4VHfW6ldHnvckBie3OjeR?= NF3HO3lU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHN? Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
A549, PC9 NHu5R2FHfW6ldHnvckBie3OjeR?= M3nT[nNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iUFO5JINmdGy| NW\6W3F3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
HCC827 M{Xv[2Fxd3C2b4Ppd{Bie3OjeR?= M4HUdGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
NCI-H1975 MUDGeY5kfGmxbjDhd5NigQ>? NGKzXmNKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R? NGj3XWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUmwOlEyPCd-Mkm5NFYyOTR:L3G+
A431 MUfGeY5kfGmxbjDhd5NigQ>? M1T6OHNmdGWldHn2bZR6KHKjdHnvMEBz[XSrbzDJR|UxKG[xcjDoeY1idiCDNEOxJINmdGy|IH;2[ZJmgHC{ZYPzbY5oKHerbHSteJlx\SCHR1\SJJRwKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDlfJBz\XO|aX7nJGVITlJiVEe5NG0wVDh3OGKgcZV1[W62 MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|MU[zPUc,OjdzM{G2N|k9N2F-
PC9 M3fxcWFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= NY\r[3BbSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gVGM6KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25iYXP0bZZifGmwZzDteZRidnRieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZz;kZZktKHCxIIHkJIZweiB5IHThfZMhemWuYYTpeoUhfG9iY3;ueJJwdA>? NF;LW|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
A431 NFXCZVRCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= M1nPNWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0N|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u NYLZenh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-EGFR / p-AKT / p-ERK; 

PubMed: 28416483     


PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib.

ABCB1; 

PubMed: 27649127     


The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.

28416483 27649127
Growth inhibition assay
Cell viability; 

PubMed: 31043587     


Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. *P < 0.05, **P < 0.01, ***P < 0.005 by t-test.

31043587
Immunofluorescence
Ki67 / γH2AX / p16; 

PubMed: 29212784     


PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. **P ≤ 0.01, ***P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.

29212784
体内試験 AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

- 合併
  • 動物モデル: Mice bearing PC9 and H1975 xenograft tumors
  • 投薬量: ~5 mg/kg
  • 投与方法: p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 99 mg/mL (198.15 mM) warming
Water Insoluble
Ethanol '43 mg/mL warmed '43
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
混合させたのち直ちに使用することを推奨します。
7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 499.61
化学式

C28 H33 N7 O2

CAS No. 1421373-65-0
Storage powder
in solvent
別名 Mereletinib
Smiles CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02841579 Completed Drug: Osimertinib Non-Small Cell Lung Cancer MedSIR|AstraZeneca August 2016 Phase 2
NCT02771314 Active not recruiting Drug: AZD9291 Non Small Cell Lung Cancer Hellenic Oncology Research Group August 2 2016 Phase 2
NCT02511106 Active not recruiting Drug: AZD9291 80 mg/40 mg|Drug: Placebo AZD9291 80 mg/40 mg Stage IB-IIIA Non-small Cell Lung Carcinoma AstraZeneca October 21 2015 Phase 3
NCT02529995 Completed Drug: AZD9291 40 mg|Drug: AZD9291 80 mg Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca August 24 2015 Phase 1
NCT02491944 Completed Drug: AZD9291|Drug: [14C]AZD9291 Oncology AstraZeneca July 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • 回答:

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Tags: Osimertinib (AZD9291)を買う | Osimertinib (AZD9291) ic50 | Osimertinib (AZD9291)供給者 | Osimertinib (AZD9291)を購入する | Osimertinib (AZD9291)費用 | Osimertinib (AZD9291)生産者 | オーダーOsimertinib (AZD9291) | Osimertinib (AZD9291)化学構造 | Osimertinib (AZD9291)分子量 | Osimertinib (AZD9291)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID